BioMérieux, discovers novel SPECIFIC REVEAL® Rapid Antimicrobial Susceptibility Test (AST) System.
SPECIFIC REVEAL® provides innovative diagnostics to support antimicrobial stewardship.
Currently there are no alternative treatments available, and over currently cleared alternatives, SPECIFIC REVEAL® Rapid AST System offers efficient advantages.
In Europe, SPECIFIC REVEAL® Rapid AST System, acquired on-market demand under CE-IVD (assay panel) and IVDR (instrument) designation provides phenotypic antibiotic susceptibility test resulting in an average of 5.5 hours2 results obtained from a positive blood culture, enables same-day antibiotic decision-making for patients suffering from bacteremic sepsis, Bacteremic sepsis is considered to be the one of the most fast-moving and life-threatening disease of all medical conditions.
U.S. Food and Drug Administration (FDA) grants Breakthrough Device Designation for the SPECIFIC REVEAL® Rapid Antimicrobial Susceptibility Test (AST) System.
